scholarly journals TNFα-Mediated Priming of Mesenchymal Stem Cells Enhances Their Neuroprotective Effect on Retinal Ganglion Cells

2020 ◽  
Vol 61 (2) ◽  
pp. 6 ◽  
Author(s):  
Ben Mead ◽  
Xitiz Chamling ◽  
Donald J. Zack ◽  
Zubair Ahmed ◽  
Stanislav Tomarev
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Retinal Ganglion Cells ◽  
Ganglion Cells ◽  
Neuroprotective Effect ◽  
Retinal Ganglion ◽  
Mediated Priming

Treatment of traumatic optic neuropathy using human placenta-derived mesenchymal stem cells in Asian patients

2020 ◽  
Vol 15 (10) ◽  
pp. 2163-2179
Author(s):  
Youngje Sung ◽  
Sang Min Lee ◽  
Mira Park ◽  
Hye Jeong Choi ◽  
Sukho Kang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Optic Nerve ◽  
Retinal Ganglion Cells ◽  
Optic Neuropathy ◽  
Ganglion Cells ◽  
Retinal Ganglion ◽  
Traumatic Optic Neuropathy ◽  
Asian Patients

Aim: To assess the safety and feasibility of subtenon transplantation of human placenta-derived mesenchymal stem cells (hPMSCs) in Asian patients with traumatic optic neuropathy. Materials & methods: The survival of retinal ganglion cells in the rat retina was evaluated by monitoring the expression of Tuj1 and Gfap after optic nerve compression. Based on the preclinical data, we conducted a Phase I, open label, single center, nonrandomized clinical trial in four Asian traumatic optic neuropathy patients. The safety and ophthalmologic changes were evaluated. Results: The levels of Tuj1 and Gfap expression were significantly increased in the hPMSC treatment group compared with the sham group, suggesting a protective effect of hPMSCs on the optic nerve and retinal ganglion cells. There was no evidence of adverse proliferation, tumorigenicity, severe inflammation or other serious issues during the 12-month follow-up period. Visual acuity improved in all four patients. Conclusion: The results suggested that hPMSCs are safe and have potential utility in regenerative medicine. Clinical trial registration number: 20150196587 (Korean FDA), 2015-07-123-054 (IRB).

Sign in / Sign up

Export Citation Format

Share Document